FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					0. 00	,000,000	(11) 01 1110 1	iivestiiieiit	0011	ipariy 7 tot o	1 10-10							
1. Name and Address of Reporting Person* CARLSON MARILYN R.					2. Issuer Name and Ticker or Trading Symbol Evoke Pharma Inc [EVOK]							(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below)					
(Last) (First) (Middle) C/O EVOKE PHARMA, INC. 420 STEVENS AVENUE, SUITE 370														below) below) Chief Medical Officer				
(Street) SOLANA BEACH CA 92075					4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																		
			able I - Non			_		1	Disp									
1. Title of Security (Instr. 3)			- 1	2. Transac Date (Month/Da	Execution Day/Year) if any		emed ion Date, a/Day/Year)	Code (Instr. 8)		4. Securitie Disposed (es Acquired Of (D) (Instr	(A) or . 3, 4 and 5)	Beneficial Owned Fo Reported	ly (D) or (I) (Ins		Direct II Indirect E tr. 4)	7. Nature of ndirect Beneficial Dwnership Instr. 4)	
									v	Amount	(A) or (D)	Price	Transactio					
			Table II - [osed of, onvertib			Owned					
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date curity or Exercise (Month/Day/Year		3A. Deemed Execution Date if any (Month/Day/Yea	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following		Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares		Reported Transact (Instr. 4)	ion(s)			
Stock Option (Right to Buy)	\$3.07	06/17/2019		D			50,000	(1)		01/27/2026	Common Stock	50,000	(2)	0	D			
Stock Option (Right to Buy)	\$3.04	06/17/2019		D			75,000	(3)		02/04/2026	Common Stock	75,000	(4)	0		D		
Stock Option (Right to Buy)	\$3.04	06/17/2019		D			33,750	(3)		02/04/2026	Common Stock	33,750	(5)	0		D		
Stock Option (Right to Buy)	\$2.36	06/17/2019		D			100,000	(6)		01/24/2027	Common Stock	100,000	(7)	0		D		
Stock Option (Right to Buy)	\$2.43	06/17/2019		D			125,000	(8)		02/06/2028	Common Stock	125,000	(9)	0		D		
Stock Option (Right to Buy)	\$2.94	06/17/2019		D			125,000	(10)		02/05/2029	Common Stock	125,000	(11)	0		D		
Stock Option (Right to Buy)	\$0.62	06/17/2019		A		37,500		(12)		01/27/2026	Common Stock	37,500	\$0.00	37,50	00	D		
Stock Option (Right to Buy)	\$0.62	06/17/2019		A		56,250		(12)		02/04/2026	Common Stock	56,250	\$0.00	56,25	50	D		
Stock Option (Right to Buy)	\$0.62	06/17/2019		A		25,312		(12)		02/04/2026	Common Stock	25,312	\$0.00	25,3:	12	D		
Stock Option (Right to Buy)	\$0.62	06/17/2019		A		75,000		(12)		01/24/2017	Common Stock	75,000	\$0.00	75,00	00	D		
Stock Option (Right to Buy)	\$0.62	06/17/2019		A		93,750		(12)		02/06/2028	Common Stock	93,750	\$0.00	93,75	50	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3A. Deemed Execution Date, if any (Month/Day/Year)	n Date, Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$0.62	06/17/2019		A		93,750		(12)	02/05/2028	Common Stock	93,750	\$0.00	93,750	D	

Explanation of Responses:

- 1. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2016, subject to the reporting person's continued service to the Issuer through each such vesting date.
- 2. On June 17, 2019, the Issuer canceled an option granted on January 28, 2016. In exchange for the canceled option, the reporting person received 37,500 options to purchase common stock.
- 3. The total number of shares of common stock subject to the option vests in 36 equal monthly installments over the three-year period beginning on January 1, 2016, subject to the reporting person's continued service to the Issuer through each such vesting date.
- 4. On June 17, 2019, the Issuer canceled an option granted on February 5, 2016. In exchange for the canceled option, the reporting person received 56,250 options to purchase common stock.
- 5. On June 17, 2019, the Issuer canceled an option granted on February 5, 2016. In exchange for the canceled option, the reporting person received 25,312 options to purchase common stock.
- 6. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2017, subject to the reporting person's continued service to the Issuer through each such vesting date.
- 7. On June 17, 2019, the Issuer canceled an option granted on January 25, 2017. In exchange for the canceled option, the reporting person received 75,000 options to purchase common stock.
- 8. The option grant date was February 7, 2018, subject to approval of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "Plan") by the Issuer's stockholders which occurred at the Issuer's annual stockholder meeting on April 26, 2018. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2018, subject to the reporting person's continued service to the Issuer through each such vesting date. Notwithstanding the foregoing vesting schedule, in no event may the option be exercised prior to the earlier of (i) the date on which the Issuer receives marketing approval from the U.S. Food and Drug Administration of Gimoti, (ii) the second anniversary of the date of grant, or (iii) the date of a "change in control" under Section 2.9 of the Plan.
- 9. On June 17, 2019, the Issuer canceled an option granted on February 7, 2018. In exchange for the canceled option, the reporting person received 93,750 options to purchase common stock.
- 10. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date.
- 11. On June 17, 2019, the Issuer canceled an option granted on February 6, 2019. In exchange for the canceled option, the reporting person received 93,750 options to purchase common stock.
- 12. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on June 17, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date.

Remarks:

/s/ Matthew J. D'Onofrio,
Attorney-in-fact for Marilyn R. 06/19/2019
Carlson

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.